• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sirion Biotech to open new office in Boston

Sirion Biotech to open new office in Boston

June 22, 2015
CenterWatch Staff

Sirion Biotech, a viral vector platform company creating viral vector solutions for industry and academic partners headquartered in Germany, has committed to opening a new office in the vicinity of Boston.

Sirion is working with the Massachusetts Life Sciences Center (MLSC) to locate lab and office space for the company, which will prove to be a pivotal step in Sirion’s U.S. expansion. Sirion’s office in the Boston area will allow direct access to Massachusetts' life science community, which includes an increasing number of biotechnology companies and academic researchers working to develop gene therapies and vaccines for a range of diseases.

"We appreciate the assistance from Massachusetts Life Sciences Center in helping us begin building our U.S. operations in the Boston area," said Dieter Lingelbach, chief operating officer of Sirion Biotech. "We are a growing company, planning to build on the success we've had in Europe, Israel and Japan, as we collaborate with many companies pioneering gene therapies."

Sirion provides customizable versions of all three major viral vector types, adenovirus, adeno-associated virus and lentivirus, and offers experience in transduction of various cell lines, an essential piece of all genetic applications. 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing